Search Within

Mark Andrew Dickson

Formats
  1. Journal Article (84)
  2. Meeting Abstract (83)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Department of Medicine (169)
  2. Sarcoma Service (169)
  3. Solid Tumor Oncology Division (169)
  4. GSK Faculty (92)
  5. Hematologic Malignancies, Division of (86)
  6. Tow Center for Developmental Oncology (TCDO) (78)

More Groups

People
  1. William Tap (90)
  2. Sandra D'Angelo (83)
  3. Mary Keohan (75)
  4. Mrinal Gounder (69)
  5. Li-Xuan Qin (56)
  6. Ping Chi (54)

More People

Years
  1. 2025 (3)
  2. 2024 (13)
  3. 2023 (13)
  4. 2022 (19)
  5. 2021 (6)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Clinical Cancer Research (17)
  3. Annals of Oncology (8)
  4. European Journal of Cancer (5)
  5. Nature Communications (5)
  6. The Oncologist (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (75)
  2. American Association for Cancer Research (20)
  3. Elsevier Inc. (14)
  4. Oxford University Press (13)
  5. Nature Publishing Group (10)
  6. Springer (6)

More Publishers

Results (169)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer
    Meeting Abstract

    Schwartz, G. K.; Dickson, M. A.; Callahan, L. A.; Darby, C. H.; Llorente, M.; Cao, Y.; Dials, H. J.; Miller, L. L.; Miao, H. H.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors
    Meeting Abstract

    Dickson, M. A.; Rathkopf, D. E.; Grant, S.; Roberts, J. D.; Reid, J. M.; Ames, M. M.; McGovern, R. M.; Gonen, M.; Dials, H. J.; Schwartz, G. K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Journal Article

    Dickson, M. A.; Shah, M. A.; Rathkopf, D.; Tse, A.; Carvajal, R. D.; Wu, N.; Lefkowitz, R. A.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Cancer Chemotherapy and Pharmacology (2010)

    Fulltext@MSK | Save
  • A phase I clinical trial of FOLFIRI in combination with the pancyclin-dependentkinase (CDK) inhibitor flavopiridol
    Meeting Abstract

    Dickson, M. A.; Carvajal, R. D.; Shah, M.; Tse, A. N.; Dials, H.; Cane, L. M.; Schwartz, G. K.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
    Journal Article

    Rathkopf, D.; Dickson, M. A.; Feldman, D. R.; Carvajal, R. D.; Shah, M. A.; Wu, N.; Lefkowitz, R.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save
  • Development of cell-cycle inhibitors for cancer therapy
    Journal Article

    Dickson, M. A.; Schwartz, G. K.
    Current Oncology (2009)

    Fulltext@MSK | Save
  • A phase I study of FOLFOX administered with flavopiridol (F) in patients with refractory solid tumors
    Meeting Abstract

    Dickson, M. A.; Carvajal, R. D.; Shah, M. A.; Cane, L. M.; Dials, H. J.; Schwartz, G. K.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors
    Meeting Abstract

    Schwartz, G. K.; Yazji, S.; Mendelson, D. S.; Dickson, M. A.; Johnston, S. H.; Wang, E. W.; Shannon, P.; Pace, L.; Gordon, M. S.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: Outcome with ICE-based treatment
    Meeting Abstract

    Hamlin, P. A.; Dickson, M.; Kewalramani, T.; Horwitz, S. M.; Portlock, C. S.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
    Blood (2006)

    Fulltext@MSK | Save